Cargando…

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women

The aim of the study was to determine an association of TP53 codon 72 (Arg72Pro, G>C transversion, rs1042522) and MDM2 SNP309 (T>G change, rs2279744) polymorphisms in endometrial cancer (EC) of postmenopausal women, regarding grading and staging of EC. In the study, endometrial samples from 20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zając, Agnieszka, Smolarz, Beata, Stachowiak, Grzegorz, Wilczyński, Jacek R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2014
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197345/ https://www.ncbi.nlm.nih.gov/pubmed/25316267 http://dx.doi.org/10.1007/s12032-014-0286-z

Ejemplares similares

Associations between Single Nucleotide Polymorphisms from the Genes of Chemokines and the CXCR2 Chemokine Receptor and an Increased Risk of Endometrial Cancer
por: Wujcicka, Wioletta Izabela, et al.
Publicado: (2023)

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer
por: YONEDA, TOMOKO, et al.
Publicado: (2013)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)

Hemostatic disorders of the menopausal period: the role of microRNA
por: Stachowiak, Grzegorz, et al.
Publicado: (2015)

TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients
por: Di Vuolo, Valeria, et al.
Publicado: (2011)

Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms
por: Cabezas, Maria, et al.
Publicado: (2019)

Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer
por: Stumbryte, Ausra, et al.
Publicado: (2017)

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
por: McGraw, Kathy L., et al.
Publicado: (2015)

Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population
por: Xiao, Mang, et al.
Publicado: (2010)

Investigation of ATM, TP53 and MDM2 polymorphisms and their association with outcome of radiotherapy for prostate cancer
por: Cintra, Hellen S, et al.
Publicado: (2013)

The significance of markers in the diagnosis of endometrial cancer
por: Żyła, Monika M., et al.
Publicado: (2016)

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
por: Drummond, Catherine J., et al.
Publicado: (2016)

Uncommon non-oncogenic HPV genotypes, TP53 and MDM2 genes polymorphisms in HIV-infected women in Southern Brazil
por: Entiauspe, Ludmila Gonçalves, et al.
Publicado: (2014)

Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
por: Hori, Yasuki, et al.
Publicado: (2015)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Association of Single Nucleotide Polymorphism LEP-R c.668A>G (p.Gln223Arg, rs1137101) of leptin receptor gene with endometrial cancer
por: Bieńkiewicz, Jan, et al.
Publicado: (2021)

Impact on breast cancer susceptibility and clinicopathological traits of common genetic polymorphisms in TP53, MDM2 and ATM genes in Sardinian women
por: Floris, Matteo, et al.
Publicado: (2022)

Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway
por: Zhanfeng, Niu, et al.
Publicado: (2016)

Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation
por: Tracz-Gaszewska, Zuzanna, et al.
Publicado: (2017)

Correction: Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
Publicado: (2015)

MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer
por: Xue, Li, et al.
Publicado: (2015)

TP53 and MDM2 Gene Polymorphisms, Gene-Gene Interaction, and Hepatocellular Carcinoma Risk: Evidence from an Updated Meta-Analysis
por: Peng, Qiliu, et al.
Publicado: (2013)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
por: Arnhold, Viktor, et al.
Publicado: (2017)

Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review
por: Yu, Meijia, et al.
Publicado: (2022)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

ATRT-08. TARGETING THE TP53-MDM2 ENHANCES RADIATION SENSITIVITY IN ATRT
por: Alimova, Irina, et al.
Publicado: (2021)

Association of polymorphisms in the 5′ untranslated region of RAD51 gene with risk of endometrial cancer in the Polish population
por: Michalska, Magdalena M., et al.
Publicado: (2014)

The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer
por: Adamczyk-Gruszka, Olga, et al.
Publicado: (2022)

MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53
por: Makii, Chinami, et al.
Publicado: (2016)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk
por: Eiholzer, Ramona A., et al.
Publicado: (2020)

An update of the classical Bokhman's dualistic model of endometrial cancer
por: Wilczyński, Miłosz, et al.
Publicado: (2016)

The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children
por: He, Jing, et al.
Publicado: (2017)

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Sinilnikova, O M, et al.
Publicado: (2009)

Loss of FBXO7 results in a Parkinson's‐like dopaminergic degeneration via an RPL23–MDM2–TP53 pathway
por: Stott, Simon RW, et al.
Publicado: (2019)

Mammographic breast density and IGF-1 gene polymorphisms rs1520220, rs2946834 and rs6219 in Polish women
por: Smolarz, Beata, et al.
Publicado: (2021)

Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients
por: Schmidt, Marjanka K, et al.
Publicado: (2009)

The Connection between the Endometrial Thickness and the Risk of Endometrial Malignancy in Postmenopausal Women
por: Tofiloska, Valentina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bong2o1ojj94loc44ri77btb74